The early foundations of this international network were laid by Cilag (1936) and Janssen Pharmaceutica (1953). Both companies established medical marketing and sales operations in various countries to support the medicines discovered in their laboratories. When, in the early 1990s, healthcare systems around the world underwent massive changes, it was decided to combine these local operations under a single name, Janssen-Cilag, in countries where both had a presence. This unified structure allows increased flexibility and customer responsiveness, and ensures the optimum use of resources. The local companies are responsible for registration, clinical development, medical information and sales in the local markets.

Today, Janssen-Cilag is a leading pharmaceutical company: it has more than 22,000 employees worldwide, establishments in 40 countries and it markets its products in almost all the countries in the world. Even as health-care systems worldwide change rapidly, our mission remains constant: we are determined to play a constructive role in dealing with the issue of health care costs by providing our customers with innovative, cost-effective products and services that enhance the quality of care and patient outcomes.

In Europe, Australia and Mexico, our products are distributed by Janssen-Cilag. In the USA and Canada, they are marketed under the Janssen Pharmaceutica, Ortho Biotech, Ortho-McNeil and Janssen-Ortho labels. In some Asian countries, such as China (Xian-Janssen), Japan (Janssen-Kyowa) and South Korea (Janssen Korea), Janssen Pharmaceutica has set up a joint venture with one or more local partners. Since beginning 2002 the company in Japan is fully under control of J&J. In most other Asian countries, our medicines are marketed by Janssen-Cilag.